Bryan Cox
Chief Tech/Sci/R&D Officer at TRISALUS LIFE SCIENCES, INC.
Net worth: 620 743 $ as of 2024-05-30
Bryan Cox active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-08-09 | - |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Chief Executive Officer | 2018-10-31 | - |
Career history of Bryan Cox
Former positions of Bryan Cox
| Companies | Position | Start | End |
|---|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | 1995-12-31 | 2012-12-31 |
Training of Bryan Cox
| University of Iowa | Doctorate Degree |
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
Statistics
International
| United States | 6 |
Operational
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Health Technology |
- Stock Market
- Insiders
- Bryan Cox
- Experience
